OTLK
|OUTLOOK THERAPEUTICS INC
NASDAQ
USD 1.77
-0.05|-2.75%
Current Price
USD 1.77
Change
USD -0.05 (-2.75%)
P/E Ratio
0.46
Dividend Yield
Market Cap
80.14M
Volume
480,276
Open
USD 1.84
Previous Close
USD 1.82
52-Week High
USD 9.25
52-Week Low
USD 0.87
About OUTLOOK THERAPEUTICS INC
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. The company wa...
Sector:Healthcare
Industry:Biotechnology
CEO:Mr. Lawrence A. Kenyon CPA
Employees:23
Headquarters:Iselin, USA
Website:www.outlooktherapeutics.com
Dividend History
Dividend Payments
| Declared Date | Record Date | Payment Date | Amount | Frequency |
|---|
Similar Companies
Explore Stocks by Sector
technology
finance
healthcare
Frequently Asked Questions